Business Description
Captor Therapeutics SA
ISIN : PLCPTRT00014
Total Employee Number:
91Description
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.61 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.73 | |||||
Beneish M-Score | 3.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -26.2 | |||||
3-Year EBITDA Growth Rate | -1.2 | |||||
3-Year EPS without NRI Growth Rate | 5.6 | |||||
3-Year FCF Growth Rate | -7.5 | |||||
3-Year Book Growth Rate | -43.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 167.05 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.32 | |||||
9-Day RSI | 35.63 | |||||
14-Day RSI | 38.89 | |||||
3-1 Month Momentum % | -1.5 | |||||
6-1 Month Momentum % | -3.78 | |||||
12-1 Month Momentum % | 109.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.6 | |||||
Cash Ratio | 1.39 | |||||
Days Sales Outstanding | 213.49 | |||||
Days Payable | 2858.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.7 | |||||
Shareholder Yield % | 0.53 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.99 | |||||
Operating Margin % | -1854.7 | |||||
Net Margin % | -1790.64 | |||||
EBITDA Margin % | -1609.87 | |||||
FCF Margin % | -3071.66 | |||||
OCF Margin % | -3063.85 | |||||
ROE % | -127.13 | |||||
ROA % | -88.93 | |||||
ROIC % | -307.78 | |||||
3-Year ROIIC % | 619.13 | |||||
ROC (Joel Greenblatt) % | -863.48 | |||||
ROCE % | -120.5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 42.07 | |||||
PS Ratio | 170.14 | |||||
PB Ratio | 33.73 | |||||
Price-to-Tangible-Book | 37.12 | |||||
EV-to-EBIT | -10.64 | |||||
EV-to-EBITDA | -11.76 | |||||
EV-to-Revenue | 189.26 | |||||
EV-to-FCF | -6.33 | |||||
Price-to-GF-Value | 7.26 | |||||
| Price-to-Net-Current-Asset-Value | 61.76 | |||||
| Price-to-Net-Cash | 106.52 | |||||
Earnings Yield (Greenblatt) % | -9.4 | |||||
FCF Yield % | -15.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Captor Therapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | 2.382 | ||
| EPS (TTM) (zł) | -7.76 | ||
| Beta | 0.9153 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.45 | ||
| Volatility % | 44.13 | ||
| 14-Day RSI | 38.89 | ||
| 14-Day ATR (zł) | 2.133294 | ||
| 20-Day SMA (zł) | 76.17 | ||
| 12-1 Month Momentum % | 109.28 | ||
| 52-Week Range (zł) | 33 - 89.2 | ||
| Shares Outstanding (Mil) | 6.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Captor Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Captor Therapeutics SA Stock Events
| Event | Date | Price (zł) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-09-11 | In 59 days | ||
| General meeting for 2025 | 2026-06-19 13:00 | 76.50 (+2.00%) | ||
| First quarter earnings conference call for 2026 | 2026-06-02 11:30 | 75.00 (-1.57%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 78.00 (+1.96%) | ||
| Analyst meeting for 2026 | 2026-05-06 11:30 | 79.50 (-2.21%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-06 11:30 | 79.50 (-2.21%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-06 | 79.50 (-2.21%) | ||
| Annual report for 2025 | 2026-04-30 | 80.50 (+1.64%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 51.20 (-1.16%) |
Show
Entries
Captor Therapeutics SA Frequently Asked Questions
What is Captor Therapeutics SA(WAR:CTX)'s stock price today?
The current price of WAR:CTX is zł73.50. The 52 week high of WAR:CTX is zł89.20 and 52 week low is zł33.00.
When is next earnings date of Captor Therapeutics SA(WAR:CTX)?
The next earnings date of Captor Therapeutics SA(WAR:CTX) is 2026-09-11 Est..
Does Captor Therapeutics SA(WAR:CTX) pay dividends? If so, how much?
Captor Therapeutics SA(WAR:CTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Captor Therapeutics SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers